Abstract :

Prostate cancer is a significant contributor to male cancer-related mortality. PIM1 kinase has implications in the development and progression of various cancers, particularly prostate cancer. PIM1, a serine/threonine protein kinase plays a crucial role in cellular processes including survival, growth and differentiation. In prostate cancer increased PIM1 expression is associated with a more aggressive phenotype and poorer patient outcomes. It has emerged as a promising therapeutic target for prostate cancer treatment. The development of PIM1 kinase inhibitors has greatly enhanced and progressed significantly. Different stages of clinical trials demonstrating their potential as therapeutic agents. Momordica charantia, or bitter melon has a long history in traditional medicine for various health conditions, it is very rich in secondary metabolites like triterpenoids, glycosides, alkaloids, flavonoids and phenolic acids. Bitter melon is considered to have medicinal properties including potential anticancer phytochemicals. This study employs virtual screening, molecular dynamic simulation and ADME/T analysis to explore bitter melon’s phytochemicals and their interaction with PIM1 kinase. The goal is to understand the molecular details and pharmacokinetics of bitter melon compounds evaluating their potential as therapeutic agents against prostate cancer. In our present study, it was found that out of all investigated phytochemicals catechin and gallic acid shows satisfactory result depending upon various parameters taken into consideration for conducting the study.

---

Keywords :

Cancer, molecular docking, Momordica charantia, phytochemicals, PIM1 kinase, Prostate

---

References :

1. Tursynbay, Y., Zhang, J., Li, Z., Tokay, T., Zhumadilov, Z., Wu, D., et al. (2016). Pim-1 kinase as cancer drug target: An update. Biomedical reports, 4(2), 140–146. https://doi.org/10.3892/br.2015.561
2. Warfel, N. A., & Kraft, A. S. (2015). PIM kinase (and Akt) biology and signaling in tumors. Pharmacology & therapeutics, 151, 41–49. https://doi.org/10.1016/j.pharmthera.2015.03.001
3. Narlik-Grassow, M., Blanco-Aparicio, C. and Carnero, A. (2014), The PIM Family of Serine/Threonine Kinases in Cancer. Med. Res. Rev., 34: 136-159. https://doi.org/10.1002/med.21284
4. Holder, S. L., & Abdulkadir, S. A. (2014). PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance. Current cancer drug targets, 14(2), 105–114. https://doi.org/10.2174/1568009613666131126113854

5. Luszczak, S., Kumar, C., Sathyadevan, V. K., Simpson, B. S., Gately, K. A., et al. (2020). PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer. Signal transduction and targeted therapy, 5(1), 7. https://doi.org/10.1038/s41392-020-0109-y
6. Cervantes-Gomez, F., Chen, L. S., Orlowski, R. Z., & Gandhi, V. (2013). Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clinical lymphoma, myeloma & leukemia, 13 Suppl 2(0 2), S317–S329. https://doi.org/10.1016/j.clml.2013.05.019
7. Peters, T. L., Li, L., Tula-Sanchez, A. A., Pongtornpipat, P., et al. (2016). Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447. Oncotarget, 7(39), 63362–63373. https://doi.org/10.18632/oncotarget.11457
8. Alam, M., Abbas, K., Ali, M., Kamal, S., & Bhagia, S. (2023). An in-silico study encompassing virtual screening and ADME/T properties of phytochemicals present in leaf extract of Trapa natans in relevance to sodium taurocholate co-transporting polypeptide involved in hepatitis B. Journal of Pharmacognosy and Phytochemistry, 12(1), 641-652.
9. Alam, M., & Abbas, K. (2021). An insight into neurodegenerative disorders, their therapeutic approaches and drugs available for tackling with neurodegeneration: a review. IAR Journal of Medical Case Reports, 2(3).
10. Abbas, K., Alam, M., Ali, V., & Ajaz, M. (2023). Virtual screening, molecular docking and ADME/T properties analysis of neuroprotective property present in root extract of chinese skullcap against β-site amyloid precursor protein cleaving enzyme 1 (BACE1) in case of alzheimer’s disease. Journal of Pharmacognosy and Phytochemistry, 12(1), 146-153.
11. Joseph, B., & Jini, D. (2013). Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pacific Journal of Tropical Disease, 3(2), 93–102. https://doi.org/10.1016/S2222-1808(13)60052-3
12. Li, C. J., Tsang, S. F., Tsai, C. H., Tsai, H. Y., Chyuan, J. H., & Hsu, H. Y. (2012). Momordica charantia Extract Induces Apoptosis in Human Cancer Cells through Caspase- and Mitochondria-Dependent Pathways. Evidence-based complementary and alternative medicine : eCAM, 2012, 261971. https://doi.org/10.1155/2012/261971
13. Jia, S., Shen, M., Zhang, F., & Xie, J. (2017). Recent Advances in Momordica charantia: Functional Components and Biological Activities. International journal of molecular sciences, 18(12), 2555. https://doi.org/10.3390/ijms18122555
14. Raina, K., Kumar, D., & Agarwal, R. (2016). Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy. Seminars in cancer biology, 40-41, 116–129. https://doi.org/10.1016/j.semcancer.2016.07.002
15. Schrödinger, L., & DeLano, W. (2020). PyMOL. Retrieved from http://www.pymol.org/pymol
16. O’Boyle, N. M. (2011). Banck M. James CA Morley C. Vandermeersch T. Hutchison GR Open Babel: An open chemical toolbox. J. Cheminf, 3(1), 33.
17. Dallakyan, Sargis & Olson, Arthur. (2015). Small-Molecule Library Screening by Docking with PyRx. Methods in molecular biology (Clifton, N.J.). 1263. 243-250. 10.1007/978-1-4939-2269-7_19.
18. Trott, O., & Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry, 31(2), 455-461.
19. Biovia, D.S. (2021) Discovery Studio Modeling Environment. Dassault Syst. Release, San Diego, 4.
20. Laskowski R A, Swindells M B (2011). LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model., 51, 2778-2786. [PubMed id: 21919503]
21. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). In vitro models for selection of development candidatesexperimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev, 23(1), 3-25.
22. Cheng, F., Li, W., Zhou, Y., Shen, J., Wu, Z., Liu, G., … & Tang, Y. (2012). admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties.
23. Banerjee, P., & Eckert, O. (2018). A.; Schrey, AK; Preissner, R. ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res, 46, W257-W263.
24. Filimonov D.A., Lagunin A.A., Gloriozova T.A., Rudik A.V., Druzhilovskii D.S., Pogodin P.V., Poroikov V.V. (2014). Prediction of the biological activity spectra of organic compounds using the PASS online web resource. Chemistry of Heterocyclic Compounds, 50 (3), 444-457.